Dr Reddy's Labs has signed a deal with U.S.-based biotech Amgen to market its three drugs used to treat heart diseases and cancer in India.
Dr Reddy's will market and distribute Amgen's Kyprolis, Blincyto, and Repatha drugs in India.
The U.S. FDA just granted approval last week for Kyprolis in combination with Revlimid and dexamethasone for the treatment of relapsed multiple myeloma -- a second multiple myeloma indication for Kyprolis.
Read the Times of India release